FDAnews
www.fdanews.com/articles/175245-federal-court-strips-purdue-of-4-oxycontin-patents

Federal Court Strips Purdue of 4 OxyContin Patents

February 8, 2016

A federal appellate court panel has stripped Purdue Pharma of four patents protecting the pain drug OxyContin from generic competition.

A three-judge panel for the U.S. Court of Appeals for the Federal Circuit unanimously upheld a district court ruling invalidating four of the company’s patents for an abuse-deterrent formulation of the drug.

The ruling, which stems from patent challenges brought by Mylan Pharmaceuticals, Teva Pharmaceuticals, Epic Pharma and Amneal Pharmaceuticals, does not leave OxyContin ripe for generic competition, however, as Purdue still holds six patents on the drug. While there are generic versions of the drug, these are authorized versions produced under licensure from Purdue.

Read the decision here: www.fdanews.com/02-02-16-Ruling.pdf.